FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898037963> ?p ?o ?g. }

• W2898037963 endingPage "e182311" @default.
• W2898037963 startingPage "e182311" @default.
• W2898037963 abstract "<h3>Importance</h3> De novo statin therapy in patients receiving chronic dialysis has failed to demonstrate cardiovascular (CV) protection in randomized clinical trials and thus is not recommended by current guidelines. However, current guidelines recommend the continuation of statin therapy if initiated before transition to dialysis. <h3>Objective</h3> To investigate whether the continuation of statins from advanced chronic kidney disease into the dialysis therapy period is associated with improved survival. <h3>Design, Setting, and Participants</h3> Retrospective cohort study of US veterans transitioning to dialysis between October 1, 2007, and March 30, 2014. Participants were 14 298 US veterans who were receiving statins during the 12-month period before transition to dialysis and survived the first year of dialysis. Data analysis was conducted between August 2, 2017, and June 28, 2018. <h3>Exposures</h3> Patients were characterized as statin continuers (n = 11 936) if statin therapy was continued for at least 6 months during the first year after dialysis initiation and as statin discontinuers (n = 2362) if therapy with statins was stopped or no statin therapy was received in the year posttransition. <h3>Main Outcomes and Measures</h3> Associations of statin continuation with 12-month all-cause mortality and CV mortality after 1 year of dialysis initiation were examined using Cox proportional hazards regression models adjusted for demographics and comorbidities. <h3>Results</h3> The mean (SD) age of the cohort was 71 (10) years; the cohort was 96.7% (n = 13 828) male and 21.3% (n = 3043) African American, and 74.6% (n = 10 627) had diabetes. The 12-month all-cause mortality and CV mortality rates after 1 year of transition to dialysis were lower in statin continuers: deaths per 100 person-years were 21.9 (95% CI, 20.9-22.8) and 8.1 (95% CI, 7.5-8.6) in statin continuers vs 30.3 (95% CI, 27.8-32.8) and 9.8 (95% CI, 8.3-11.2) in statin discontinuers. Moreover, lower all-cause mortality and CV mortality risks with statin continuation persisted in adjusted analyses, with hazard ratios of 0.72 (95% CI, 0.66-0.79) and 0.82 (95% CI, 0.69-0.96), respectively. Associations were similar across subgroups, including age, race, and diabetes status. <h3>Conclusions and Relevance</h3> In this study, the continuation of statin therapy after transition to dialysis was associated with reduced all-cause mortality and CV mortality. The study findings suggest that future studies are needed to examine potential CV benefits of continuing statin therapy after dialysis initiation." @default.
• W2898037963 created "2018-10-26" @default.
• W2898037963 creator A5037829607 @default.
• W2898037963 creator A5047209550 @default.
• W2898037963 creator A5047313234 @default.
• W2898037963 creator A5059472417 @default.
• W2898037963 creator A5074587712 @default.
• W2898037963 creator A5084375517 @default.
• W2898037963 creator A5087074877 @default.
• W2898037963 creator A5088002863 @default.
• W2898037963 date "2018-10-05" @default.
• W2898037963 modified "2023-10-14" @default.
• W2898037963 title "Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation" @default.
• W2898037963 cites W1154365502 @default.
• W2898037963 cites W1483531931 @default.
• W2898037963 cites W1667887382 @default.
• W2898037963 cites W1755389849 @default.
• W2898037963 cites W1826064705 @default.
• W2898037963 cites W1978239396 @default.
• W2898037963 cites W2000313374 @default.
• W2898037963 cites W2003121310 @default.
• W2898037963 cites W2031185570 @default.
• W2898037963 cites W2047498248 @default.
• W2898037963 cites W2086488691 @default.
• W2898037963 cites W2101729820 @default.
• W2898037963 cites W2110601215 @default.
• W2898037963 cites W2112304946 @default.
• W2898037963 cites W2112368070 @default.
• W2898037963 cites W2120166750 @default.
• W2898037963 cites W2121363804 @default.
• W2898037963 cites W2123121206 @default.
• W2898037963 cites W2126049444 @default.
• W2898037963 cites W2134120087 @default.
• W2898037963 cites W2159036586 @default.
• W2898037963 cites W2162430779 @default.
• W2898037963 cites W2319057797 @default.
• W2898037963 cites W2335824247 @default.
• W2898037963 cites W2338802706 @default.
• W2898037963 cites W2403885063 @default.
• W2898037963 cites W2475261460 @default.
• W2898037963 cites W2512895854 @default.
• W2898037963 cites W2567699103 @default.
• W2898037963 cites W2602255804 @default.
• W2898037963 cites W2605738993 @default.
• W2898037963 cites W2610676999 @default.
• W2898037963 cites W2614096895 @default.
• W2898037963 cites W2623884423 @default.
• W2898037963 cites W2735301415 @default.
• W2898037963 cites W2755422294 @default.
• W2898037963 cites W2759078970 @default.
• W2898037963 cites W2766580889 @default.
• W2898037963 cites W2808135930 @default.
• W2898037963 cites W2915967003 @default.
• W2898037963 cites W395502118 @default.
• W2898037963 cites W4236252235 @default.
• W2898037963 cites W4250105901 @default.
• W2898037963 cites W2152022378 @default.
• W2898037963 doi "https://doi.org/10.1001/jamanetworkopen.2018.2311" @default.
• W2898037963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324660" @default.
• W2898037963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646217" @default.
• W2898037963 hasPublicationYear "2018" @default.
• W2898037963 type Work @default.
• W2898037963 sameAs 2898037963 @default.
• W2898037963 citedByCount "30" @default.
• W2898037963 countsByYear W28980379632018 @default.
• W2898037963 countsByYear W28980379632019 @default.
• W2898037963 countsByYear W28980379632020 @default.
• W2898037963 countsByYear W28980379632021 @default.
• W2898037963 countsByYear W28980379632022 @default.
• W2898037963 countsByYear W28980379632023 @default.
• W2898037963 crossrefType "journal-article" @default.
• W2898037963 hasAuthorship W2898037963A5037829607 @default.
• W2898037963 hasAuthorship W2898037963A5047209550 @default.
• W2898037963 hasAuthorship W2898037963A5047313234 @default.
• W2898037963 hasAuthorship W2898037963A5059472417 @default.
• W2898037963 hasAuthorship W2898037963A5074587712 @default.
• W2898037963 hasAuthorship W2898037963A5084375517 @default.
• W2898037963 hasAuthorship W2898037963A5087074877 @default.
• W2898037963 hasAuthorship W2898037963A5088002863 @default.
• W2898037963 hasBestOaLocation W28980379631 @default.
• W2898037963 hasConcept C126322002 @default.
• W2898037963 hasConcept C167135981 @default.
• W2898037963 hasConcept C201903717 @default.
• W2898037963 hasConcept C2776839432 @default.
• W2898037963 hasConcept C2778653478 @default.
• W2898037963 hasConcept C2779541074 @default.
• W2898037963 hasConcept C2779978075 @default.
• W2898037963 hasConcept C2910901499 @default.
• W2898037963 hasConcept C50382708 @default.
• W2898037963 hasConcept C71924100 @default.
• W2898037963 hasConcept C72563966 @default.
• W2898037963 hasConceptScore W2898037963C126322002 @default.
• W2898037963 hasConceptScore W2898037963C167135981 @default.
• W2898037963 hasConceptScore W2898037963C201903717 @default.
• W2898037963 hasConceptScore W2898037963C2776839432 @default.
• W2898037963 hasConceptScore W2898037963C2778653478 @default.
• W2898037963 hasConceptScore W2898037963C2779541074 @default.
• W2898037963 hasConceptScore W2898037963C2779978075 @default.

• next